Literature DB >> 33992860

Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone.

Rui Li1, Jingqi Wang1, Cong Li1, Xiangfu Liu2, Muyang Chu3, Yanyu Chang1, Yuge Wang1, Xia Wang4, Boguang Yu5, Li Ling3, Hui Yang6, Huan Yang7, Xueqiang Hu1, Wei Qiu8.   

Abstract

We aimed to evaluate the value of immunoadsorption (IA) treatment after the failure of intravenous methylprednisolone (IVMP) therapy for neuromyelitis optica spectrum disorder (NMOSD). Sixty-one NMOSD attacks unresponsive to IVMP were included: 22 patients received rescue IA (IVMP+IA), 24 underwent rescue plasma exchange (PE) (IVMP+PE), and 21 received no further rescue therapy (IVMP alone). The improvement frequencies were higher in the IVMP+IA and IVMP+PE groups than in the IVMP-alone group (P = 0.024). The effective period for IA treatment may be longer than previously thought. IA treatment for IVMP-resistant NMOSD attacks was effective and comparable to PE treatment.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aquaporin 4; Immunoadsorption; Methylprednisolone; Myelitis; Neuromyelitis optica; Plasmapheresis

Year:  2021        PMID: 33992860     DOI: 10.1016/j.jneuroim.2021.577604

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

1.  Efficacy of Plasma Exchange Treatment for Demyelinating Optic Neuritis Associated with Various Serum Antibodies: A Prospective Cohort Study.

Authors:  Junxia Fu; Yongping Wang; Hongen Li; Huanfen Zhou; Honglu Song; Mingming Sun; Quangang Xu; Shaoying Tan; Shihui Wei
Journal:  Neurol Ther       Date:  2022-04-09

2.  Efficacy of Combined Desensitization Therapy Based on Protein A Immunoadsorption on Anti-human Leukocyte Antigen Antibodies in Sensitized Kidney Transplant Recipients: A Retrospective Study.

Authors:  XiaoFei Chen; YuXian Wang; PeiJian Dong; JiaMei Wang; XiaoTian Yu; BoGuang Yu
Journal:  Cureus       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.